Eisai reports Phase Ib/II data for Halaven plus Keytruda in TNBC

Eisai Co. Ltd. (Tokyo:4523) reported data from 106 evaluable patients with metastatic triple-negative breast cancer (TNBC) in the Phase Ib/II ENHANCE 1 (KEYNOTE-150) trial showing that Halaven eribulin mesylate (E7389) plus

Read the full 312 word article

User Sign In